Drug Patents owned by Pharmacyclics Inc

1. Drug name - IMBRUVICA

Patent Number Company Patent Title Patent Expiry Activity Alert
These patents protects the active chemical substance. Only patent owner can launch products that use this active substance.
US8697711 PHARMACYCLICS INC Inhibitors of bruton'S tyrosine kinase
Dec, 2026

(4 years from now)

US8957079 PHARMACYCLICS INC Inhibitors of Bruton's tyrosine kinase
Dec, 2026

(4 years from now)

US9181257 PHARMACYCLICS INC Inhibitors of Bruton's tyrosine kinase
Dec, 2026

(4 years from now)

US7514444 PHARMACYCLICS INC Inhibitors of bruton's tyrosine kinase
Dec, 2026

(4 years from now)

US8735403 PHARMACYCLICS INC Inhibitors of Bruton's tyrosine kinase
Dec, 2026

(4 years from now)

US8008309 PHARMACYCLICS INC Inhibitors of bruton's tyrosine kinase
Nov, 2027

(5 years from now)

US9725455 PHARMACYCLICS INC Crystalline forms of a bruton's tyrosine kinase inhibitor
Jun, 2033

(10 years from now)

US10125140 PHARMACYCLICS INC Crystalline forms of a bruton's tyrosine kinase inhibitor
Jun, 2033

(10 years from now)

US10106548 PHARMACYCLICS INC Crystalline forms of a Bruton's tyrosine kinase inhibitor
Jun, 2033

(10 years from now)

US9296753 PHARMACYCLICS INC Crystalline forms of a Bruton's tyrosine kinase inhibitor
Oct, 2033

(11 years from now)

CN103319488A PHARMACYCLICS INC A Bruton ' S Tyrosine Kinase Inhibitor
Nov, 2016

(5 years ago)

CN104736178A PHARMACYCLICS INC Crystalline Form Of Bruton Tyrosine Kinase Inhibitor
Jan, 2020

(2 years ago)

CN102887900B PHARMACYCLICS INC Inhibitor Of Bruton ' S Tyrosine Kinase
Dec, 2026

(4 years from now)

CN102887900A PHARMACYCLICS INC Inhibitors Of Bruton'S Tyrosine Kinase
Dec, 2026

(4 years from now)

CN102746305B PHARMACYCLICS INC Inhibitor Of Bruton ' S Tyrosine Kinase
Dec, 2026

(4 years from now)

CN101805341A PHARMACYCLICS INC Inhibitors Of Bruton'S Tyrosine Kinase
Dec, 2026

(4 years from now)

CN101610676B PHARMACYCLICS INC Inhibitor Of Bruton Tyrosine Kinase
Dec, 2026

(4 years from now)

CN101805341B PHARMACYCLICS INC Inhibitors Of Bruton'S Tyrosine Kinase
Dec, 2026

(4 years from now)

CN101610676A PHARMACYCLICS INC Inhibitors Of Bruton'S Tyrosine Kinase
Dec, 2026

(4 years from now)

CN102746305A PHARMACYCLICS INC Inhibitors Of Bruton'S Tyrosine Kinase
Dec, 2026

(4 years from now)

CN101674834A PHARMACYCLICS INC A Bruton ' S Tyrosine Kinase (Bruton ' S Tyrosine Kinase Inhibitor
Mar, 2028

(5 years from now)

CN101674834B PHARMACYCLICS INC Inhibitors Of Bruton'S Tyrosine Kinase
Mar, 2028

(5 years from now)

IN201205631P1 PHARMACYCLICS INC Inhibitors Of Bruton'S Tyrosine Kinase
Dec, 2026

(4 years from now)

IN362133B PHARMACYCLICS INC Inhibitors Of Bruton&Amp;Apos;S Tyrosine Kinase
Dec, 2026

(4 years from now)

IN200901642P1 PHARMACYCLICS INC Inhibitors Of Bruton'S Tyrosine Kinase
Mar, 2029

(6 years from now)

EP2529622B1 PHARMACYCLICS INC Inhibitors Of Bruton'S Tyrosine Kinase
Feb, 2019

(3 years ago)

EP2529622A1 PHARMACYCLICS INC Inhibitors Of Bruton'S Tyrosine Kinase
Feb, 2019

(3 years ago)

EP2201840B1 PHARMACYCLICS INC Inhibitors Of Bruton'S Tyrosine Kinase
Jul, 2020

(2 years ago)

EP2201840A1 PHARMACYCLICS INC Inhibitors Of Bruton'S Tyrosine Kinase
Jul, 2020

(2 years ago)

EP2526933A3 PHARMACYCLICS INC Inhibitors Of Bruton'S Tyrosine Kinase
Dec, 2026

(4 years from now)

EP2081435B1 PHARMACYCLICS INC Inhibitors Of Bruton'S Tyrosine Kinase
Dec, 2026

(4 years from now)

EP2081435A4 PHARMACYCLICS INC Inhibitors Of Bruton'S Tyrosine Kinase
Dec, 2026

(4 years from now)

EP2526771A1 PHARMACYCLICS INC Inhibitors Of Bruton'S Tyrosine Kinase
Dec, 2026

(4 years from now)

EP2526933B1 PHARMACYCLICS INC Inhibitors Of Bruton'S Tyrosine Kinase
Dec, 2026

(4 years from now)

EP2530083A1 PHARMACYCLICS INC Inhibitors Of Bruton'S Tyrosine Kinase
Dec, 2026

(4 years from now)

EP2081435A2 PHARMACYCLICS INC Inhibitors Of Bruton'S Tyrosine Kinase
Dec, 2026

(4 years from now)

EP2530083B1 PHARMACYCLICS INC Inhibitors Of Bruton'S Tyrosine Kinase
Dec, 2026

(4 years from now)

EP2526771B1 PHARMACYCLICS INC Inhibitors Of Bruton'S Tyrosine Kinase
Dec, 2026

(4 years from now)

EP2526933A2 PHARMACYCLICS INC Inhibitors Of Bruton'S Tyrosine Kinase
Dec, 2026

(4 years from now)

EP2526934A3 PHARMACYCLICS INC Inhibitors Of Bruton'S Tyrosine Kinase
Dec, 2026

(4 years from now)

EP2526934A2 PHARMACYCLICS INC Inhibitors Of Bruton'S Tyrosine Kinase
Dec, 2026

(4 years from now)

EP2529621B1 PHARMACYCLICS INC Inhibitors Of Bruton'S Tyrosine Kinase
Dec, 2026

(4 years from now)

EP2529621A1 PHARMACYCLICS INC Inhibitors Of Bruton'S Tyrosine Kinase
Dec, 2026

(4 years from now)

EP2526934B1 PHARMACYCLICS INC Inhibitors Of Bruton'S Tyrosine Kinase
Dec, 2026

(4 years from now)

EP2139487A2 PHARMACYCLICS INC Inhibitors Of Bruton'S Tyrosine Kinase
Mar, 2028

(5 years from now)

EP2139487B1 PHARMACYCLICS INC Inhibitors Of Bruton'S Tyrosine Kinase
Mar, 2028

(5 years from now)

EP2139487A4 PHARMACYCLICS INC Inhibitors Of Bruton'S Tyrosine Kinase
Mar, 2028

(5 years from now)

These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US8754091 PHARMACYCLICS INC Inhibitors of bruton's tyrosine kinase Dec, 2026

(4 years from now)

US8476284 PHARMACYCLICS INC Inhibitors of Bruton's tyrosine kinase Dec, 2026

(4 years from now)

US8703780 PHARMACYCLICS INC Inhibitors of Bruton's tyrosine kinase Dec, 2026

(4 years from now)

US8952015 PHARMACYCLICS INC Inhibitors of Bruton's tyrosine kinase Dec, 2026

(4 years from now)

US8497277 PHARMACYCLICS INC Inhibitors of Bruton's tyrosine kinase Dec, 2026

(4 years from now)

US8563563 PHARMACYCLICS INC Inhibitors of bruton's tyrosine kinase Apr, 2027

(4 years from now)

US10478439 PHARMACYCLICS INC Use of inhibitors of bruton's tyrosine kinase (Btk) Jun, 2031

(8 years from now)

US9801883 PHARMACYCLICS INC Use of inhibitors of bruton's tyrosine kinase (Btk) Jun, 2031

(8 years from now)

US9125889 PHARMACYCLICS INC Use of inhibitors of Bruton's tyrosine kinase (Btk) Jun, 2031

(8 years from now)

US9801881 PHARMACYCLICS INC Use of inhibitors of bruton's tyrosine kinase (BTK) Jun, 2031

(8 years from now)

US8754090 PHARMACYCLICS INC Use of inhibitors of bruton's tyrosine kinase (Btk) Jun, 2031

(8 years from now)

US8999999 PHARMACYCLICS INC Use of inhibitors of Bruton's tyrosine kinase (Btk) Jun, 2031

(8 years from now)

US10004746 PHARMACYCLICS INC Use of inhibitors of Bruton's tyrosine kinase (Btk) Jun, 2031

(8 years from now)

US10016435 PHARMACYCLICS INC Use of inhibitors of Bruton's tyrosine kinase (Btk) Jun, 2031

(8 years from now)

US9814721 PHARMACYCLICS INC Use of inhibitors of bruton'S tyrosine kinase (BTK) Jun, 2031

(8 years from now)

US10751342 PHARMACYCLICS INC Use of inhibitors of Bruton's tyrosine kinase (Btk) Jun, 2031

(8 years from now)

US10653696 PHARMACYCLICS INC Use of inhibitors of bruton's tyrosine kinase (BTK) Jun, 2031

(8 years from now)

US10752634 PHARMACYCLICS INC Crystalline forms of a brutons tyrosine kinase inhibitor Jun, 2033

(10 years from now)

US10961251 PHARMACYCLICS INC Crystalline forms of a Bruton's tyrosine kinase inhibitor Jun, 2033

(10 years from now)

US10294232 PHARMACYCLICS INC Crystalline forms of a Bruton's tyrosine kinase inhibitor Jun, 2033

(10 years from now)

US9713617 PHARMACYCLICS INC Crystalline forms of a Bruton's tyrosine kinase inhibitor Jun, 2033

(10 years from now)

US10294231 PHARMACYCLICS INC Crystalline forms of a Bruton's tyrosine kinase inhibitor Jun, 2033

(10 years from now)

US9540382 PHARMACYCLICS INC Crystalline forms of a Bruton's tyrosine kinase inhibitor Aug, 2033

(10 years from now)

US9795604 PHARMACYCLICS INC Methods of treating and preventing graft versus host disease Oct, 2034

(12 years from now)

US10463668 PHARMACYCLICS INC Methods of treating and preventing graft versus host disease Oct, 2034

(12 years from now)

US10695350 PHARMACYCLICS INC Methods of treating and preventing graft versus host disease Oct, 2034

(12 years from now)

US9655857 PHARMACYCLICS INC Pharmaceutical formulations of a Bruton's tyrosine kinase inhibitor Mar, 2036

(13 years from now)

US10010507 PHARMACYCLICS INC Pharmaceutical formulations of a bruton's tyrosine kinase inhibitor Mar, 2036

(13 years from now)

US10213386 PHARMACYCLICS INC Pharmaceutical formulations of a Bruton's tyrosine kinase inhibitor Mar, 2036

(13 years from now)

US10828259 PHARMACYCLICS INC Pharmaceutical formulations of a Bruton's tyrosine kinase inhibitor Mar, 2036

(13 years from now)

Drugs and Companies using IBRUTINIB ingredient

Treatment: Treatment of waldenstrom's macroglobulinemia; treatment of mantle cell lymphoma; treatment of marginal zone lymphoma; treatment of small lymphocytic lymphoma; Treatment of chronic lymphocytic leukemia; treatment of chronic lymphocytic leukemia with 17p deletion; Treatment of small lymphocytic lymphoma; treatment of chronic lymphocytic leukemia with 17p deletion; treatment of small lymphocytic lymphoma with 17p deletion; treatment of mantle cell lymphoma; treatment of marginal zone lymphoma; treatment of chronic lymphocytic leukemia; treatment of waldenstrom's macroglobulinemia; Treatment of chronic lymphocytic leukemia with 17p deletion; treatment of waldenstrom's macroglobulinemia; treatment of mantle cell lymphoma; treatment of small lymphocytic lymphoma; treatment of chronic lymphocytic leukemia; treatment of marginal zone lymphoma; treatment of small lymphocytic lymphoma with 17p deletion; Treatment of waldenstrom's macroglobulinemia; treatment of small lymphocytic lymphoma; treatment of chronic lymphocytic leukemia; treatment of chronic lymphocytic leukemia with 17p deletion; treatment of small lymphocytic lymphoma with 17p deletion; Treatment of chronic lymphocytic leukemia with 17p deletion; treatment of waldenstrom's macroglobulinemia; treatment of small lymphocytic lymphoma; treatment of chronic graft versus host disease after failure of one or more lines of systemic therapy; treatment of mantle cell lymphoma; treatment of small lymphocytic lymphoma with 17p deletion; treatment of marginal zone lymphoma; treatment of chronic lymphocytic leukemia; Treatment of chronic lymphocytic leukemia/small lymphocytic lymphoma; For the treatment of patients with waldenstrom's macroglobulinemia; treatment of waldenstrom's macroglobulinemia; Treatment of chronic lymphocytic leukemia; Treatment of mantle cell lymphoma; Treatment of chronic lymphocytic leukemia; treatment of small lymphocytic leukemia; treatment of chronic lymphocytic leukemia; treatment for chronic lymphocytic leukemia with 17p deletion; treatment of small lymphocytic lymphoma; Treatment of chronic lymphocytic leukemia with 17p deletion; treatment of small lymphocytic lymphoma with 17p deletion; treatment of small lymphocytic lymphoma; treatment of chronic lymphocytic leukemia; Treatment of waldenstrom's macroglobulinemia; Treatment of marginal zone lymphoma; Treatment of relapsed or refractory small lymphocytic lymphoma; treatment of small lymphocytic lymphoma; treatment of chronic lymphocytic leukemia; treatment of relapsed or refractory chronic lymphocytic leukemia; Treatment of marginal zone lymphoma; treatment of mantle cell lymphoma; treatment of chronic lymphocytic leukemia; treatment of small lymphocytic lymphoma; treatment of waldenstrom's macroglobulinemia; treatment of chronic lymphocytic leukemia; Treatment of adult patients with chronic graft-versus-host disease (cgvhd) after failure of one or more lines of systemic therapy; treatment of adult patients with cyclosporin-resistant, steroid-dependent/refractory, or steroid resistant chronic graft-versus-host disease (cgvhd) after failure of one or more lines of systemic therapy; Treatment of refractory chronic graft-versus-host disease; Treatment of chronic graft versus host disease refractory to systemic therapy

Dosage: TABLET;ORAL

More Information on Dosage
Strength Dosage Availability
140MG TABLET;ORAL Prescription
280MG TABLET;ORAL Prescription
420MG TABLET;ORAL Prescription
560MG TABLET;ORAL Prescription

availability in other generic markets.

Click on the highlighted region to filter.